BRPI0911436A2 - vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado - Google Patents

vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado

Info

Publication number
BRPI0911436A2
BRPI0911436A2 BRPI0911436A BRPI0911436A BRPI0911436A2 BR PI0911436 A2 BRPI0911436 A2 BR PI0911436A2 BR PI0911436 A BRPI0911436 A BR PI0911436A BR PI0911436 A BRPI0911436 A BR PI0911436A BR PI0911436 A2 BRPI0911436 A2 BR PI0911436A2
Authority
BR
Brazil
Prior art keywords
dna
proteins
pharmaceutical compositions
vectors encoding
injured tissue
Prior art date
Application number
BRPI0911436A
Other languages
English (en)
Portuguese (pt)
Inventor
Katsuto Tamai
Takehiko Yamazaki
Takenao Chino
Yasufumi Kaneda
Original Assignee
Genomix Co Ltd
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomix Co Ltd, Univ Osaka filed Critical Genomix Co Ltd
Publication of BRPI0911436A2 publication Critical patent/BRPI0911436A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0911436A 2008-04-30 2009-04-30 vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado BRPI0911436A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
PCT/JP2009/058519 WO2009133940A1 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬

Publications (1)

Publication Number Publication Date
BRPI0911436A2 true BRPI0911436A2 (pt) 2016-07-12

Family

ID=41255155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911436A BRPI0911436A2 (pt) 2008-04-30 2009-04-30 vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado

Country Status (10)

Country Link
US (1) US20110097309A1 (enExample)
EP (1) EP2301560A4 (enExample)
JP (3) JP5814549B2 (enExample)
KR (1) KR20110027665A (enExample)
CN (1) CN102076351A (enExample)
AU (1) AU2009240885A1 (enExample)
BR (1) BRPI0911436A2 (enExample)
CA (1) CA2722906A1 (enExample)
RU (1) RU2010148785A (enExample)
WO (1) WO2009133940A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
KR20110017371A (ko) 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
CN103687946B (zh) 2011-04-26 2017-05-03 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
CN104955470B (zh) * 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
EP3349793B1 (en) * 2015-09-14 2021-08-11 Université Laval Anti-s100a8 for treating leukemia
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
CA3059544A1 (en) 2017-04-25 2018-11-01 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CN110709506A (zh) * 2017-07-18 2020-01-17 株式会社资生堂 间充质干细胞导引剂
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) * 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院（同济大学附属东方医院） 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666B (zh) * 2025-09-22 2026-02-10 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU4328801A (en) * 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US20040191246A1 (en) * 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
EP1390058A2 (en) * 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
EP1402068A4 (en) * 2001-05-09 2006-07-12 Univ Cleveland Hospitals EVALUATION OF SKIN DAMAGE CAUSED BY ULTRAVIOLET RAYS USING NEW GENE MARKERS, METHODS AND COMPOSITIONS THEREOF
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20040265971A1 (en) * 2001-11-19 2004-12-30 Hidetaka Sato Drug mobilizing pluripotent stem cells from tissue into peripheral blood
JP2005537253A (ja) * 2002-07-03 2005-12-08 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール 組織損傷の治療におけるおよび／または組織修復を促進するためのｈｍｇｂ１の使用
DE60327075D1 (de) * 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
DE602004017148D1 (de) * 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2574548A1 (en) * 2004-07-20 2006-01-26 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
KR20110017371A (ko) * 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
WO2009133939A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬

Also Published As

Publication number Publication date
JPWO2009133940A1 (ja) 2011-09-01
EP2301560A1 (en) 2011-03-30
RU2010148785A (ru) 2012-06-10
AU2009240885A1 (en) 2009-11-05
EP2301560A4 (en) 2012-05-09
JP5960735B2 (ja) 2016-08-02
CA2722906A1 (en) 2009-11-05
KR20110027665A (ko) 2011-03-16
WO2009133940A1 (ja) 2009-11-05
CN102076351A (zh) 2011-05-25
JP2016104790A (ja) 2016-06-09
JP5814549B2 (ja) 2015-11-17
US20110097309A1 (en) 2011-04-28
AU2009240885A2 (en) 2011-01-27
JP2014139177A (ja) 2014-07-31

Similar Documents

Publication Publication Date Title
BRPI0911436A2 (pt) vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado
BRPI0908876A2 (pt) barreiras para facilitação de reações biológicas
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
EP2257155A4 (en) Cryopreservation of biological cells and tissues
PT3178490T (pt) Composições de proteína f de rsv e métodos para produção das mesmas
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
HUE036759T2 (hu) CRY1Ca és CRY1Fa proteinek kombinált alkalmazása rovarrezisztencia menedzselésére
PT2173324T (pt) Gel injetável de ácido hialurónico para tratamento de degenerescências articulares
EP2391208A4 (en) COMPOSITIONS FOR THE TREATMENT OF NAILS AND SKIN
BRPI0812575A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos
EP3699291C0 (en) METHODS FOR ANALYZING UNIQUE NUCLEIC ACID SEQUENCE AND COMPOSITIONS
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
BRPI1011655A2 (pt) uso de lcat para tratar anemia e disfunção de glóbulos vermelhos
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
EP2226331A4 (en) PROCESS FOR CLEANING PROTEINS
HUE037061T2 (hu) Specifikusan kötõdõ fehérjék és alkalmazásuk
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0922619A2 (pt) compostos de plasmalogen, composições farmacêuticas contendo os mesmos e métodos para tratar doenças do envelhecimento
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
EP2833883A4 (en) NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
BRPI0908334A2 (pt) kit, composição, produto ou medicamento para tratar comprometimento cognitivo
BRPI0912157A8 (pt) manufatura de bolsas para conter espécimes biológicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL